Daicel chiral columns

By Press release
Tuesday, 27 January, 2009


Daicel is a specialist chromatography column manufacturer and commenced the development of Chiral columns in the 1980s. Using its expertise in cellulose chemistry Daicel developed Chiral Stationary Phases (CSPs); these are made with silica support onto which the polymeric chiral selector (polysaccharide derivatives) has been immobilised. The immobilisation of polysaccharide derivatives on a matrix has been considered as a revolutionary approach to implement universal solvent compatibility on these highly selective chiral stationary phases for enantio separations. The technique broadens the range of solvents that may be used as mobile phases, thereby allowing new selectivity profiles. As a result of this, Daicel Chemical Industries has expanded its product line from the original coated CSPs to the immobilised type using proprietary immobilisation technologies now marketed under the brands CHIRALPAK. CHIRALPAKIA, IB, and IC are the first immobilised CSPs to become commercially available. Their unique solvent flexibility and excellent chiral recognition ability make them an ideal choice for chiral separations. Key features of the CHIRALPAK column range: high solvent versatility in the selection of mobile phase composition; solvent flexibility for the separation of compounds with limited solubility; excellent column efficiency and ease of use. The major advantage of an immobilised polysaccharide CSP is that it can be used with any organic miscible solvent in the mobile phase.

Scientex

Email: info@scientex.com.au

Related Articles

Could 'fusion proteins' reduce errors in a promising gene-editing tool?

Gene-editing tool CRISPR-Cas9 is used, among many things, to engineer new cancer immunotherapies....

Cancer research and clinical trials at the core of new centre

The Australian Cancer Research Foundation Centre for Dynamic Immuno-Oncology (CDIO) has been...

Potential biological targets for vascular dementia

Caused by damage to blood vessels in the brain, there is currently no approved treatment for...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd